SERA vs NTRA vs PGNY vs OVID vs INVA

For growth investors, Ovid Therapeutics Inc.

(OVID) is the stronger pick with 1181% revenue growth year-over-year, versus 5. 2% for Sera Prognostics, Inc. (SERA). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Sera Prognostics, Inc. (SERA) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Innoviva, Inc.

(INVA) is the cheapest at 6. 9x versus Progyny, Inc. at 29. 5x. On forward P/E, Innoviva, Inc. is actually cheaper at 11. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Innoviva, Inc. wins at 1. 15x versus Progyny, Inc. 's 2. 45x — a reasonable growth-adjusted valuation.

Over the past 5 years, Natera, Inc.

(NTRA) delivered a total return of +115. 9%, compared to -83. 9% for Sera Prognostics, Inc. (SERA). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus SERA's -83. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 13β versus Sera Prognostics, Inc. 's 1. 56β — meaning SERA is approximately 1137% more volatile than INVA relative to the S&P 500. On balance sheet safety, Ovid Therapeutics Inc. (OVID) carries a lower debt/equity ratio of 1% versus 23% for Innoviva, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ovid Therapeutics Inc.

(OVID) is pulling ahead at 1181% versus 5. 2% for Sera Prognostics, Inc. (SERA). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to 0. 7% for Natera, Inc.. Over a 3-year CAGR, OVID leads at 69. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -394. 2% for Sera Prognostics, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -450. 7% for SERA. At the gross margin level — before operating expenses — OVID leads at 95. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Innoviva, Inc. (INVA) is the more undervalued stock at a PEG of 1. 15x versus Progyny, Inc. 's 2. 45x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Innoviva, Inc. (INVA) trades at 11. 9x forward P/E versus 16. 4x for Progyny, Inc. — 4. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SERA: 160. 4% to $5. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Innoviva, Inc.

(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 13)). Sera Prognostics, Inc. (SERA) carries a higher beta of 1. 56 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INVA: +94. 9%, SERA: -83. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SERA is a small-cap quality compounder stock; NTRA is a mid-cap high-growth stock; PGNY is a small-cap quality compounder stock; OVID is a small-cap high-growth stock; INVA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.